View Future GrowthRevvity 과거 순이익 실적과거 기준 점검 0/6Revvity의 수입은 연평균 -38.3%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 3.5% 감소했습니다. 매출은 연평균 9.9%의 비율로 감소해 왔습니다. Revvity의 자기자본이익률은 3.3%이고 순이익률은 8.2%입니다.핵심 정보-38.35%순이익 성장률-39.93%주당순이익(EPS) 성장률Life Sciences 산업 성장률21.51%매출 성장률-9.93%자기자본이익률3.33%순이익률8.24%최근 순이익 업데이트05 Apr 2026최근 과거 실적 업데이트Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.37. Revenue: US$711.1m (up 7.0% from 1Q 2025). Net income: US$40.9m (down 1.9% from 1Q 2025). Profit margin: 5.8% (down from 6.3% in 1Q 2025). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.4%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.공시 • Apr 11Revvity, Inc. to Report Q1, 2026 Results on May 05, 2026Revvity, Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026Reported Earnings • Feb 02Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$2.06 (down from US$2.31 in FY 2024). Revenue: US$2.86b (up 3.7% from FY 2024). Net income: US$239.9m (down 15% from FY 2024). Profit margin: 8.4% (down from 10% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 8% per year.Reported Earnings • Oct 28Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$0.41 (down from US$0.76 in 3Q 2024). Revenue: US$698.9m (up 2.2% from 3Q 2024). Net income: US$47.2m (down 49% from 3Q 2024). Profit margin: 6.8% (down from 14% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.공시 • Oct 06Revvity, Inc. to Report Q3, 2025 Results on Oct 27, 2025Revvity, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 27, 2025분석 기사 • Aug 14Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings SuggestNYSE:RVTY 1 Year Share Price vs Fair Value Explore Revvity's Fair Values from the Community and select yours Even...모든 업데이트 보기Recent updates분석 기사 • 17hRevvity (RVTY) Stock Could Be 10.9% Undervalued Despite Profit And Growth PressureRevvity (RVTY) is back in focus after recent commentary highlighted weak organic revenue growth, declining adjusted operating profits, and ongoing annual earnings per share pressure. These factors are sharpening questions about the stock’s core business performance. See our latest analysis for Revvity. At a share price of $101.22, Revvity’s recent 30-day share price return of 7.72% and 90-day gain of 19.18% suggest momentum has picked up, even though the 5-year total shareholder return is...내러티브 업데이트 • Jun 15RVTY: Elevated Multiple And China Exit Will Test 2026 ExecutionRevvity's analyst fair value estimate has shifted from $95.00 to $90.00 as analysts factor in more measured assumptions for revenue growth, profit margins, and a higher future P/E, while also weighing recent price target moves and mixed ratings across the Street. Analyst Commentary Recent Street research on Revvity shows a mix of views, with several firms adjusting ratings and price targets in different directions.속보 • Jun 06Revvity Tops Q1 Estimates and Updates 2026 Outlook With China Unit Divestiture PlanRevvity reported Q1 2026 revenue of $711.1 million, up 7% year over year, with adjusted EPS of $1.06 coming in about 4% above Wall Street estimates. The company posted 3% total organic growth and an adjusted operating margin of 23.6% to 24%, supported by contributions from Life Sciences, Diagnostics and SaaS software. Revvity plans to divest its China Immunodiagnostics business, which represented about 6% of 2025 revenue, and expects the move to reduce adjusted EPS by about $0.15 in 2026 while lifting future organic growth by roughly 100 basis points and operating margins by about 30 basis points annually on a pro forma basis. The key story here is a business that is meeting or slightly topping expectations in the near term while reshaping its portfolio by exiting a segment that management views as a drag on growth and margins. Investors may want to weigh the near-term EPS headwind from the divestiture against the company’s updated 2026 guidance, which on a pro forma basis now points to $2.81 billion to $2.84 billion in revenue, adjusted EPS of $5.20 to $5.30 and organic growth of 3% to 4%. They may also want to monitor insider selling activity that has been reported over the past six months.내러티브 업데이트 • Jun 01RVTY: Q1 Execution And Tools Demand Will Support Measured Future Earnings PowerRevvity's updated analyst price target has shifted to $113.64 from $119.56. This reflects a mix of recent target cuts and raises as analysts factor in revised growth and profitability assumptions, as well as a higher future P/E outlook.Declared Dividend • May 11Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th July 2026 Payment date: 7th August 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 13%. Cash payout ratio: 6%.분석 기사 • May 08Revvity, Inc. (NYSE:RVTY) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Shareholders of Revvity, Inc. ( NYSE:RVTY ) will be pleased this week, given that the stock price is up 14% to US$98.85...Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.37. Revenue: US$711.1m (up 7.0% from 1Q 2025). Net income: US$40.9m (down 1.9% from 1Q 2025). Profit margin: 5.8% (down from 6.3% in 1Q 2025). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.4%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.공시 • May 06Revvity, Inc. Updates Earnings Guidance for the Full Year 2026Revvity, Inc. Updated earnings guidance for the full year 2026. For the period, the company forecasts total revenue of $2.81-$2.84 billion.내러티브 업데이트 • May 05RVTY: Cautious 2026 Tools Recovery Setup Will Face Execution DebateRevvity's updated analyst price target edges lower by $4 to reflect revised expectations following several price target cuts and a downgrade, partly offset by a recent upgrade from one research firm. Analyst Commentary Recent Street research on Revvity reflects a cautious tone, with several bearish analysts trimming price targets and reassessing expectations.공시 • May 02Revvity, Inc. announces Quarterly dividend, payable on August 07, 2026Revvity, Inc. announced Quarterly dividend of USD 0.0700 per share payable on August 07, 2026, ex-date on July 17, 2026 and record date on July 17, 2026.내러티브 업데이트 • Apr 21RVTY: 2026 Tools Recovery Setup Will Face Mixed Execution DebateThe analyst fair value estimate for Revvity has been reset from $105 to $95, as analysts weigh recent target cuts alongside mixed rating changes and revised assumptions for growth, margins, and future P/E multiples. Analyst Commentary Recent Street research on Revvity has sent mixed signals, with several price target adjustments and at least one downgrade alongside an upgrade.공시 • Apr 17Revvity, Inc. Showcases Integrated Cancer Research Solutions At AACR Annual Meeting 2026Revvity, Inc. was showcasing its latest innovations in cancer research at the AACR Annual Meeting 2026, to be held in San Diego, April 17-22. The Company’s comprehensive suite of research use only (RUO) oncology solutions are designed to elevate preclinical and translational research workflows, helping scientists accelerate discoveries that drive the future of cancer science. The full scope of Revvity’s integrated oncology solutions and reagents that will be on display are designed to support the entire cancer research workflow from sample preparation and assay development, to advanced imaging, detection, and data analysis. By combining innovative technologies with AI-driven insights, Revvity helps researchers generate high-quality, reproducible data and uncover deeper biological insights faster. Attendees will experience several of Revvity’s latest innovations, including: Opera Phenix™ OptIQ high-content screening system for advanced 3D and live-cell imaging; Living Image™ Synergy AI software for multimodal in vivo imaging data analysis; EnVision Nexus™ One multimode plate reader for high-sensitivity detection and performance; AssayMate™ automated workstation for simplified, accessible sample preparation; Dharmacon™ ON-TARGETplus™ 2.0 siRNA for potent on-target mRNA knockdown with siRNA designed against the modern genome; Next-generation reagents and assay solutions, such as ATPlite™ and Spark PLUS UV395™, designed to enhance workflow consistency and data quality. Together, these solutions reflect Revvity’s strategy to deliver integrated technologies that connect workflows, reduce variability, and enable more confident decision-making in cancer research, including advanced cellular imaging, AI-enabled in vivo analysis, high-performance detection, automation, and genomics tools. By bringing together instrumentation, reagents, software, and services, Revvity supports researchers at every stage of the scientific journey, helping overcome complex research challenges, increase productivity, and translate discoveries into meaningful impact. For research use only. Not for use in diagnostic procedures. Not affiliated with or endorsed by AACR.공시 • Apr 11Revvity, Inc. to Report Q1, 2026 Results on May 05, 2026Revvity, Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026Upcoming Dividend • Apr 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 April 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.2%). Lower than average of industry peers (0.7%).공시 • Apr 09Revvity Inc Announces Signals Biodesign Cloud-Native Molecular Cloning SolutionRevvity, Inc. announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration. The Signals BioDesign offering provides a complete solution for designing therapeutic constructs across core cloning workflows including Golden Gate, Gibson assembly, and restriction/ligation, plus primer design, Sanger sequencing analysis, and protein translation in one simple to use application. The solution enables high-throughput combinatorial cloning for up to 1,000 constructs while maintaining workflow simplicity, allowing pharma and biotech researchers to design faster, collaborate seamlessly, and eliminate costly data silos. As the only cloud-native molecular cloning tool with integration in the Signals One platform, the Signals BioDesign solution connects design with existing bioregistration and multi-modal experiment capture in a unified biologics research ecosystem. The cloud-native architecture enables real-time team collaboration, centralized bio-sequence libraries, duplicate checking, monomer management, and granular access controls that desktop tools cannot provide, while multi-tenant SaaS deployment eliminates the administrative overhead and compliance risks associated with desktop software licensing. The Signals BioDesign solution’s AI-ready data infrastructure also positions research teams for future machine learning applications in sequence optimization and predictive design. Revvity will introduce the Signals BioDesign offering at the Bio-IT World Conference & Expo, May 19-21, in Boston, Massachusetts.내러티브 업데이트 • Apr 06RVTY: Recent Upgrade Cycle And Q4 Execution Will Drive Future UpsideRevvity's updated analyst price target edges up from $137.63 to $140.00 as analysts factor in a mix of recent target increases from several firms and a more cautious stance from at least one large bank. Analyst Commentary The latest Street research on Revvity reflects a split view, with several bullish analysts lifting price targets and one large bank taking a more cautious approach.내러티브 업데이트 • Mar 23RVTY: 2026 Tools Recovery Setup Will Support Healthier End MarketsRevvity’s analyst price targets have shifted higher by a few dollars across several firms, with analysts pointing to healthier end markets, improving procedure and CapEx trends into 2026, early recovery signs in China, and expectations for the company’s tools exposure as key supports for the updated valuations. Analyst Commentary Recent Street research on Revvity has centered on how much recovery in tools demand and procedure volumes is already reflected in current valuations.공시 • Mar 09Revvity, Inc., Annual General Meeting, Apr 28, 2026Revvity, Inc., Annual General Meeting, Apr 28, 2026.내러티브 업데이트 • Mar 08RVTY: 2026 Tools Demand And China Recovery Will Support Higher Earnings PowerRevvity's analyst price target edges higher from $114.63 to $119.56 as analysts factor in updated assumptions around discount rates, modestly slower revenue growth and slightly lower profit margins, along with a higher future P/E multiple supported by a series of recent target raises from Baird, TD Cowen, Evercore ISI, Barclays and Jefferies. Analyst Commentary Bullish analysts have been lifting their price targets in a fairly tight range, which points to a shared view that Revvity's risk or return profile has shifted enough to justify higher valuation assumptions, even as they factor in tempered expectations for revenue growth and margins.내러티브 업데이트 • Feb 22RVTY: Fair Value View Weighs 2026 Recovery Against Policy And China RisksAnalysts have nudged their targets on Revvity higher, with recent $3 to $6 price target increases clustered around a fresh $112 mark. They cite recovering end markets, healthier procedure and CapEx trends into 2026, and early signs of improvement in China as key supports for the updated view.내러티브 업데이트 • Feb 08RVTY: Fair Value View Balances Margin Upside With Policy And China RisksAnalysts have lifted their implied fair value for Revvity by $5 to $105, citing updated assumptions around profit margins, a lower future P/E multiple, and recent price target increases from several firms as key drivers of the recalibration. Analyst Commentary Recent Street research on Revvity has centered on fine tuning price targets and reassessing how much investors are willing to pay for the company, with several firms adjusting their models around margin expectations and appropriate P/E levels.Declared Dividend • Feb 08Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th April 2026 Payment date: 8th May 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 14%. Cash payout ratio: 6%.공시 • Feb 05Revvity, Inc. Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations At SLAS2026Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are theOpera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include: Opera Phenix OptIQ high- content screening system: Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60% to 95%, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony software building block enables detection of organoids in brightfield image stacks. EnVision Nexus One multimode plates reader: The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the EnVision Nexus platform in a streamlined single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows. AssayMate workstation: The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3-1000 uL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling--including detection of missing plate lids--enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP software provides a user-friendly, drag-and-drop interface that requires minimal training.Recent Insider Transactions Derivative • Feb 03Key Executive notifies of intention to sell stockTajinder Vohra intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of February. If the sale is conducted around the recent share price of US$105, it would amount to US$602k. Since March 2025, Tajinder's direct individual holding has decreased from 22.63k shares to 19.35k. Company insiders have collectively sold US$335k more than they bought, via options and on-market transactions in the last 12 months.공시 • Feb 03Revvity, Inc. Provides Revenue Guidance Full Year Ending January 3, 2027Revvity, Inc. provided revenue guidance full year ending January 3, 2027. For the fiscal year 2026, the Company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%.Reported Earnings • Feb 02Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$2.06 (down from US$2.31 in FY 2024). Revenue: US$2.86b (up 3.7% from FY 2024). Net income: US$239.9m (down 15% from FY 2024). Profit margin: 8.4% (down from 10% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 8% per year.공시 • Jan 27Revvity, Inc. Declares Quarterly Dividend, Payable on May 8, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026.내러티브 업데이트 • Jan 25RVTY: Q4 Margin Ramp And Sector Recovery Thesis Will Drive UpsideNarrative Update Analysts have lifted their price target on Revvity by about US$4 to reflect modestly higher fair value estimates and slightly stronger assumptions for revenue growth, Q4 execution and sector recovery potential into 2026. Analyst Commentary Bullish analysts are leaning constructive on Revvity, pointing to recent quarterly execution, updated guidance and sector trends as support for higher valuation ranges.Major Estimate Revision • Jan 14Consensus EPS estimates increase by 18%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from US$2.06 to US$2.43. Revenue forecast steady at US$2.84b. Net income forecast to grow 45% next year vs 15% growth forecast for Life Sciences industry in the US. Consensus price target of US$115 unchanged from last update. Share price rose 8.3% to US$112 over the past week.공시 • Jan 13+ 1 more updateRevvity, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2025Revvity, Inc. provided revenue guidance for the fourth quarter and full year of 2025. For the quarter, reported and organic revenue growth is expected to be approximately 6% and 4%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $772 million. For the full year 2025, reported and organic revenue growth is expected to be approximately 4% and 3%, respectively, as compared to the same period a year ago. This is expected to result in full year 2025 revenue of approximately $2,855 million.내러티브 업데이트 • Jan 11RVTY: Q4 Margin Ramp And Buybacks Poised To Meet Cautious RecoveryThe analyst price target for Revvity has been nudged higher by about $0.25, reflecting Street analysts' generally constructive view on recovering end markets, Q4 guidance that many see as achievable, and improving sector sentiment, even as some firm specific and China related risks remain in focus. Analyst Commentary Street research on Revvity is mixed but tilts constructive, with several firms nudging price targets higher while one new initiation takes a more cautious stance.Upcoming Dividend • Jan 09Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 16 January 2026. Payment date: 06 February 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.4%). Lower than average of industry peers (0.5%).Buy Or Sell Opportunity • Jan 08Now 21% undervaluedOver the last 90 days, the stock has risen 15% to US$102. The fair value is estimated to be US$128, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.7% over the last 3 years. Earnings per share has declined by 23%. For the next 3 years, revenue is forecast to grow by 5.6% per annum. Earnings are also forecast to grow by 26% per annum over the same time period.내러티브 업데이트 • Dec 27RVTY: Q4 Margin Ramp And Buybacks Will Drive Next PhaseAnalysts have nudged their average price target on Revvity modestly higher, reflecting confidence that Q4’s steeper ramp in sales and operating margins is achievable and supported by in-line Q3 organic growth, an earnings beat, and slightly improved forward earnings guidance, despite lingering company specific and macro headwinds. Analyst Commentary Bullish analysts highlight that Q3, while not spectacular, provides a solid springboard for a steeper ramp in Q4 sales and operating margins, which they view as achievable based on in line organic growth and an earnings beat.분석 기사 • Dec 18Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...공시 • Dec 17Revvity, Inc. Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials DiscoveryRevvity, Inc. announced the introduction of its upcoming Signals Xynthetica™? Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in-silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence. Across life sciences and materials research, the application of artificial intelligence and machine learning is rapidly shifting discovery from trial-and-error experimentation toward predictive, data driven design. While powerful algorithms and models continue to emerge, their real-world impact is limited without tight integration with high-quality experimental data and the workflows scientists already use. The Signals Xynthedica offering is intended to address this gap by embedding models directly into the scientific context, connecting AI predictions with real wet-lab outcomes to drive continuous learning and improvement. The Signals Xyntetica platform will support a wide range of in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. Delivered as an AI MaaS offering, it enables organizations to access, govern, and apply predictive models without building or maintaining a complex AI infrastructure. Models can be used consistently across projects, refreshed as new data emerges, and evaluated transparently alongside experimental results. The Signals Xynthenica offering is expected to become a cornerstone of Revvity's broader vision for AI-augmented discovery, enabling customers to harness predictive power at scale while maintaining strong governance, data stewardship, and scientific rigor. Pre-registration for customers is underway with early access programs available in firstH 2026.내러티브 업데이트 • Dec 13RVTY Q4 Margin Ramp And Buybacks Will Drive Stronger Future UpsideAnalysts have modestly raised their blended price target on Revvity to approximately $105 per share, up from around $100. This change reflects increased confidence that the company can deliver a steeper but achievable ramp in Q4 sales and margins while continuing to improve profitability, despite a slightly higher discount rate and lingering near term growth risks.Buy Or Sell Opportunity • Dec 01Now 20% undervaluedOver the last 90 days, the stock has risen 17% to US$102. The fair value is estimated to be US$129, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.7% over the last 3 years. Earnings per share has declined by 23%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 29% per annum over the same time period.내러티브 업데이트 • Nov 29RVTY: Buyback Program and Guidance Outlook Will Shape Next PhaseAnalysts have increased their price target for Revvity to $105 from previous levels. They cite achievable Q4 guidance and an improved profit outlook, despite mixed quarterly results.내러티브 업데이트 • Nov 15RVTY: Recent Buyback Activity and Expanded Partnership Will Drive Near-Term MomentumRevvity's analyst price target has increased from $99 to $105 per share, as analysts cite improving guidance for the upcoming quarter and stronger than expected recent performance, while noting that some risks remain. Analyst Commentary Analyst sentiment towards Revvity has shifted positively in recent weeks, reflecting improved financial guidance and resilient performance.공시 • Nov 10Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc.Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc. on November 10, 2025. The transaction is expected to close late in Q4 2025.Declared Dividend • Nov 09Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 16th January 2026 Payment date: 6th February 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 14%. Cash payout ratio: 6%.내러티브 업데이트 • Oct 31RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery AheadAnalysts have slightly raised their fair value estimate for Revvity by $1 to $113.67. They cite more achievable Q4 guidance and improved margin prospects following the company's recent earnings updates.Reported Earnings • Oct 28Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$0.41 (down from US$0.76 in 3Q 2024). Revenue: US$698.9m (up 2.2% from 3Q 2024). Net income: US$47.2m (down 49% from 3Q 2024). Profit margin: 6.8% (down from 14% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.공시 • Oct 27Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares.Revvity, Inc. (NYSE:RVTY) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its own shares. The program is valid for 2 years.Seeking Alpha • Oct 27Revvity: Software Momentum And Screening Offset China WeaknessSummary Revvity, Inc. operates across two main segments in Life Sciences tools and Diagnostics. Its cloud informatics Signals continue experiencing double-digit growth, while diagnostics in China suffer from macro headwinds. RVTY’s latest Q3 2025 revenue figures were up 2% overall. For the most part, US and ex-China growth offsets China’s decline. In my view, its valuation is about fair, but there’s room for upside as the stock should catch up to the rest of the market given its EPS recent beat. RVTY’s cash flow remains solid, and the $1 billion buyback program should further help the stock price over the next few months. Read the full article on Seeking Alpha공시 • Oct 27Revvity, Inc. Revises Earnings Guidance for the Full Year Ending December 28, 2025Revvity, Inc. revised earnings guidance for the full year ending December 28, 2025. For the year, the company expects revenue to be between $2.83 billion to $2.88 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 2% to 4%.공시 • Oct 25Revvity, Inc. Appoints Anita Gonzales as Vice President and Chief Accounting Officer, Effective October 23, 2025On October 23, 2025, the Board of Directors of Revvity, Inc. appointed Anita Gonzales, the Company’s Vice President and Controller, to serve as its Vice President and Chief Accounting Officer, effective October 23, 2025. Mrs. Gonzales, 49, has served as the Company’s Vice President and Controller since May 2023, having joined the Company as Senior Director of Integration and Controllership Initiatives in March 2021. Prior to joining the Company, Mrs. Gonzales was at General Electric Company (“GE”) for ten years. During her tenure at GE, Mrs. Gonzales was Director of Audit and Advisory Practices Corporate division from 2016 to 2021, with responsibility for technical accounting and audit standards of the Corporate Audit Staff. Before that, Mrs. Gonzales held executive roles at GE Aviation including Global Controller-Commercial Engines. Earlier in her career, she held roles of increasing responsibility, up to Senior Manager, at PricewaterhouseCoopers. Mrs. Gonzales holds Master of Public Accounting and Bachelor of Business Administration degrees from the University of Texas at Austin and is a Certified Public Accountant.공시 • Oct 24Revvity Board Declares Quarterly Dividend, Payable on February 6, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.내러티브 업데이트 • Oct 17Digital Transformation And Advanced Diagnostics Will Create Enduring ValueThe consensus analyst price target for Revvity has decreased from $115.19 to $112.67. This change reflects lowered profit margin forecasts, slower revenue growth expectations, and continued market headwinds highlighted in recent research reports.Upcoming Dividend • Oct 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 October 2025. Payment date: 07 November 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.5%). Lower than average of industry peers (0.5%).공시 • Oct 06Revvity, Inc. to Report Q3, 2025 Results on Oct 27, 2025Revvity, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 27, 2025내러티브 업데이트 • Oct 03Digital Transformation And Advanced Diagnostics Will Create Enduring ValueAnalysts have slightly reduced their price target for Revvity by $1.63 to $115.19. They cite cautious optimism, as stable core markets are offset by ongoing sector uncertainties and revised forecasts for a slower recovery.공시 • Sep 30Revvity, Inc. Unveils New AI Software Offering to Transform Preclinical Imaging AnalysisRevvity, Inc. announced the launch of its Living Image Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities--reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. The Living Image Synergy AI software centralizes analysis with a goal of eliminating the need for separate tools and enabling seamless correlation of datasets. Revvity developed this unified approach to help researchers uncover biological insights that might otherwise remain hidden when using isolated systems. To further streamline workflows, the software features intuitive co-registration tools and automated processes that reduce manual tasks and analysis time. Advanced AI algorithms automate image segmentation and region-of-interest (ROI) quantification--traditionally labor-intensive and variable steps in imaging analysis. This helps support high-throughput analysis and allows researchers to more efficiently monitor disease progression and assess therapeutic efficacy with greater accuracy and statistical confidence.공시 • Sep 22Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD)Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD)분석 기사 • Aug 14Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings SuggestNYSE:RVTY 1 Year Share Price vs Fair Value Explore Revvity's Fair Values from the Community and select yours Even...Declared Dividend • Aug 10Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th October 2025 Payment date: 7th November 2025 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 7%.공시 • Aug 07Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted TherapeuticsRevvity, Inc. announced the launch of pHSense™? reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to- background--even at low endogenous receptor expression levels. Fully compatible with Revvity's multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows. By enabling more efficient screening and characterization of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation. With a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design focused on addressing major limitations of current offerings such as low throughput and suboptimal signal-to-noise ratios.Reported Earnings • Jul 29Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: EPS: US$0.47 (down from US$0.59 in 2Q 2024). Revenue: US$720.3m (up 4.1% from 2Q 2024). Net income: US$55.2m (down 24% from 2Q 2024). Profit margin: 7.7% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.공시 • Jul 29Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.84 billion to $2.88 billion to reflect recent changes in foreign currency exchange rates and assumes 2% to 4% organic growth.공시 • Jul 25Revvity, Inc. Declares Quarterly Dividend, Payable on November 7, 2025The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025.분석 기사 • Jul 22Investors Interested In Revvity, Inc.'s (NYSE:RVTY) EarningsWhen close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Upcoming Dividend • Jul 11Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 18 July 2025. Payment date: 08 August 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.5%). Lower than average of industry peers (0.6%).공시 • Jul 07Revvity, Inc. to Report Q2, 2025 Results on Jul 28, 2025Revvity, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 28, 2025분석 기사 • Jul 04Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101?Revvity, Inc. ( NYSE:RVTY ) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE...공시 • Jun 02Revvity, Inc. Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing WorkflowsRevvity, Inc. announced the launch of three Mimix reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requirements, which helps laboratories integrate them into existing workflows to support monitoring test performance, assay variation, and to help identify increases in random or systemic errors. Offering the Mimix reference standards for IV D indicates the products have been developed and manufactured in accordance with applicable quality system requirements allowing for improved reliability and precision of these reference standards. The three Mimix reference standards cover key cancer testing applications, which include: Mimix OncoSpan FFPE Reference Standard IVD (HD832-IVD); Mimix OncoSpan gDNA Reference Standard IVD (HD 827-IVD); Mimix Myeloid Cancer Panel, gDNA Reference Standard IVD.공시 • May 20Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty TestingRevvity, Inc. announced the launch of its new IDS i20™? analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer's disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low-throughput analyzers, the IDS i20 platform offers labs a new means of more flexible, fully automated ChLIA processing. With the ability to process up to 140 tests per hour (assay dependent), the IDS i20 instrument is the latest addition to the well-established IDS i-device series, built on more than 50 years of experience in medical device design and innovation. The IDS i20 platform features new software offering a high degree of adaptability and scalability, along with a superior graphical user interface that meets the latest standards of ergonomics, usability and cybersecurity. Continuous loading of samples and reagents as well as the integrated cooling of ready-to-use reagent cartridges allow for non-stop operation of the system - maximizing efficiency and minimizing hands-on time.Declared Dividend • May 11Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 18th July 2025 Payment date: 8th August 2025 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 6%.Reported Earnings • Apr 28First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: US$0.35 (up from US$0.23 in 1Q 2024). Revenue: US$664.8m (up 2.3% from 1Q 2024). Net income: US$41.7m (up 45% from 1Q 2024). Profit margin: 6.3% (up from 4.4% in 1Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.공시 • Apr 28Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.83-$2.87 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 3-5% for the full year 2025.공시 • Apr 25Revvity, Inc. Declares Regular Quarterly Dividend, Payable on August 8, 2025The Board of Directors of Revvity declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025.공시 • Apr 23Revvity, Inc. Fuels the Future of Cancer Science with New Research SolutionsRevvity, Inc. is set to unveil the VivoJect™? Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Meeting 2025 in Chicago, April 25-30. Paired with the Vega™? automated preclinical ultrasound system, the VivoJect system allows for real-time imaging and precise, nimble operation for researchers at a higher throughput compared to traditional techniques. It streamlines in vivo imaging workflows for applications such as tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies. Revvity will also showcase a broad portfolio of solutions driving advancements in cancer research at its booth (#1200), including the PhenoVue™? DNA Damage Response Staining Kit, Harmony™? 5.3 and Phenologic.AI™? high-content image analysis software and over 120 cell line-derived oncology reference standards from itsimix™? portfolio. BioLegend's reagent innovations will also be on display, including the TotalSeq™? PhenoCyte, TotalSeq-A and -C Universal Cocktails, v2.0, LEGEND MAX™? High Sensitivity Mouse TNF-a and ELISA MAX™? Deluxe Set Human ICAM-1 kits. Key Exhibits at AACR Annual Meeting 2025 Revvity's booth will also feature: Cell analysis in 3D, and AI: Solutions include cell counters and image cytometers, cellular imaging reagents, microplates and analysis software, as well as high-content imaging instruments. Immunoassays: An extensive range of immunoassay technologies including multimode microplate readers and microplates, as well as assay kits and reagents. In vivo imaging: Instruments, reagents, software and related accessories to help accelerate drug development by tracking disease progression, evaluate efficacy, and assess toxicity. Genomic solutions: A wide range of solutions including the Pin-point™? base editing platform, OMNI™? sample homogenizers, liquid handling workstations and more. More than 10 scientific posters authored or co-authored by Revvity employees will be on display. Among them is a poster produced in collaboration with a research team from Charles River Laboratories, which utilized Revvity's Vega automated preclinical ultrasound system in a longitudinal study of the progression of graft versus host disease. For further information on Revvity's cancer research innovations and poster presentations at the AACR Annual meeting 2025, visit booth #1200 or this link. All Revvity offerings mentioned herein are for research use only, and not for use in diagnostic procedures.Upcoming Dividend • Apr 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 April 2025. Payment date: 09 May 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.9%). Lower than average of industry peers (0.7%).Buy Or Sell Opportunity • Apr 08Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to US$91.79. The fair value is estimated to be US$118, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has declined by 54%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.공시 • Apr 03Revvity, Inc. to Report Q1, 2025 Results on Apr 28, 2025Revvity, Inc. announced that they will report Q1, 2025 results Pre-Market on Apr 28, 2025공시 • Apr 02Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis TestRevvity, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world. Key Features of the Automated Latent Tuberculosis Test: The Auto-Pure 2400 system seamlessly integrates liquid handling and magnetic cell isolation technology. The Auto-Pure 2400 system streamlines lab workflows, testing up to 24 samples per run, completing Day 1 of the T-SPOT.TB testing in under 3.5 hours with only a single mid-run user interaction. The WHO identifies T-SPOT.TB as the only ELISPOT-based IGRA. This methodology, with its added cell number normalization step, ensures reproducible results by minimizing the impact of pre-analytical variables seen in other IGRAs. The T-SPOT.TB test delivers key advantages, including fewer indeterminate results, reduced need for repeat testing, and consistent performance in immunocompromised patients.공시 • Feb 27Revvity, Inc., Annual General Meeting, Apr 22, 2025Revvity, Inc., Annual General Meeting, Apr 22, 2025.Seeking Alpha • Feb 24Revvity: Acquisitions In High-Growth Sectors, Excellent Debt Levels Create Notable Growth PotentialSummary Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position, reaching a 38.13% liabilities-to-assets ratio, the lowest value in eight years. In addition, it has improved its current ratio. Despite the fact that Revvity will face a weak demand in 2025, the two segments of Revvity expect a high growth rate in the long-term. Read the full article on Seeking AlphaDeclared Dividend • Feb 09Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th April 2025 Payment date: 9th May 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.4%. Payout Ratios Payout ratio: 12%. Cash payout ratio: 6%.Reported Earnings • Feb 01Third quarter 2024 earnings released: EPS: US$0.76 (vs US$0.26 in 3Q 2023)Third quarter 2024 results: EPS: US$0.76 (up from US$0.26 in 3Q 2023). Revenue: US$684.0m (up 2.0% from 3Q 2023). Net income: US$93.4m (up 188% from 3Q 2023). Profit margin: 14% (up from 4.8% in 3Q 2023). Revenue is forecast to grow 5.1% p.a. on average during the next 4 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.Recent Insider Transactions Derivative • Jan 31Senior VP of Administration notifies of intention to sell stockJoel Goldberg intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of January. If the sale is conducted around the recent share price of US$127, it would amount to US$1.9m. Since March 2024, Joel's direct individual holding has decreased from 104.61k shares to 97.11k. Company insiders have collectively sold US$818k more than they bought, via options and on-market transactions in the last 12 months.공시 • Jan 31Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025Revvity, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects total revenue of $2.80 billion to $2.85 billion.공시 • Jan 24+ 1 more updateRevvity, Inc. to Unveils New Phenologic.AI Software At SLAS2025 in San Diego, San DiegoRevvity, Inc. is set to unveil its groundbreaking new Phenologic.AI software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity’s Harmony™ and Signals Image Artist software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis. This significant advancement expands the possibilities for understanding cellular behaviors and disease mechanisms. The Phenologic.AI offering provides scalable, efficient, and objective analysis and can be integrated with Revvity Signals Research Suite™ to provide more in-depth data analytics. Complementing this launch, Revvity will also introduce other notable products, including the latest Harmony 5.3 software, which simplifies data management for high-content imaging and analysis, providing faster and more intuitive data handling. Key Exhibits at SLAS2025: Revvity’s featured solutions include: Assay Development and Automation: Custom automation solutions to boost throughput and reliability, including the explorer™ G3 integrated workstation. Automated Liquid Handling: The Fontus liquid handler offers intuitive software, optimized protocols, and reformatting capabilities for streamlined productivity. Cell Imaging and AI: Advanced tools like the Opera Phenix Plus HCS system, alongside the Phenologic.AI offering. Reagents Portfolio: Including PhenoVue imaging reagents, BioLegend antibodies, and Dharmacon CRISPR screening libraries. For detailed information on the showcased innovations, scientific talks, and posters, visit booth #1318 or Revvity’s SLAS2025 events page.공시 • Jan 16Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024Revvity, Inc. updated revenue guidance for the fourth quarter of 2024. For the year, the company's Reported and organic revenue growth for the fourth quarter is expected to be approximately 5% and 6%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $730 million.공시 • Jan 13Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025Revvity, Inc. announced that they will report fiscal year 2024 results Pre-Market on Jan 31, 2025Recent Insider Transactions Derivative • Jan 12Key Executive notifies of intention to sell stockTajinder Vohra intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of January. If the sale is conducted around the recent share price of US$117, it would amount to US$642k. Since March 2024, Tajinder's direct individual holding has decreased from 26.11k shares to 19.65k. Company insiders have collectively sold US$818k more than they bought, via options and on-market transactions in the last 12 months.공시 • Jan 10Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone TestRevvity, Inc. announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders. Key features of the new test include: The only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma. Rapid results on EUROIMMUN’s ChLIA platforms with the first result available in just 48 minutes and an estimated throughput of nearly 60 tests per hour. Incorporation of monoclonal antibodies to ensure specificity and consistent performance across test batches. The assay is processed on the Company’s random-access iSYS or i10 instruments to deliver quick turnaround times and high-throughput testing with minimal technician training and expertise, while maintaining superior accuracy and reliability. The assay provides direct measurement of free testosterone levels in a single test, enhancing diagnostic capabilities for conditions such as hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgenital syndromes.Upcoming Dividend • Jan 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 January 2025. Payment date: 07 February 2025. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of American dividend payers (4.6%). Lower than average of industry peers (0.5%).Seeking Alpha • Dec 16Safe Biopharma: Revvity's Recurring Revenues And DiagnosticsSummary Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company’s recurring revenue base (80%) from consumables, services, and software ensures predictable income and financial stability. The company has a global footprint and an estimated TAM exceeding $60 billion, showcasing its significant market opportunity. Yet, RVTY's valuation is relatively high compared to peers, with a forward PE of 22.7 and an earnings yield of 4.4%, reflecting its premium status. Despite sluggish revenue growth, RVTY's diversified revenue sources and strong cash flow make it a safe long-term buy in the biopharma sector. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • Dec 03CEO, President & Director notifies of intention to sell stockPrahlad Singh intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of December. If the sale is conducted around the recent share price of US$116, it would amount to US$2.1m. For the year to December 2017, Prahlad's total compensation was 12% salary and 88% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Prahlad has owned 127.36k shares directly. Company insiders have collectively bought US$18k more than they sold, via options and on-market transactions, in the last 12 months.공시 • Nov 20Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single CellsScale Biosciences (Scale BioTM) and Revvity's BioLegend business announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Biosciences' Quantum Barcoding technology platform and BioLegend's TotalSeqTM antibody conjugates. While technologies like mass cytometry and high-parameter flow cytometry enable protein analysis at the single cell level, these approaches require complex panel optimization and sophisticated instrumentation that limit their accessibility and scalability across multiple samples. The new offering builds upon BioLegend's well validated TotalSeq-ATM antibody panels and Scale Bio's Quantum Barcoding technology workflow. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation. The TotalSeq Phenocyte solution is now shipping.매출 및 비용 세부 내역Revvity가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NYSE:RVTY 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비05 Apr 262,90223991422028 Dec 252,85624091321628 Sep 252,81323292820929 Jun 252,79827993620730 Mar 252,77029693920129 Dec 242,75528393119729 Sep 242,72225894919930 Jun 242,70819794220231 Mar 242,72618394321131 Dec 232,75118094221701 Oct 232,79621389822202 Jul 232,83725090322202 Apr 233,02435391822101 Jan 233,31251394022202 Oct 223,5995991,00122203 Jul 223,74863798921903 Apr 223,48369488519502 Jan 223,82888985420003 Oct 214,1551,08689319704 Jul 214,2571,15589319704 Apr 214,4381,07496121703 Jan 212,66363172914604 Oct 203,23441288719605 Jul 202,97729486619105 Apr 202,88722684519029 Dec 192,88422883318929 Sep 192,83523580619430 Jun 192,80225179419731 Mar 192,78324779019630 Dec 182,77823780919430 Sep 182,66312876118001 Jul 182,54314971916601 Apr 182,38714766715231 Dec 172,25715761513901 Oct 172,18225858713502 Jul 172,14221558012902 Apr 172,13221058412801 Jan 172,11621658512402 Oct 161,99919857410803 Jul 162,04819958311003 Apr 162,07619058311003 Jan 162,10518958611304 Oct 152,26317666112728 Jun 152,241164657126양질의 수익: RVTY는 $94.5M 규모의 큰 일회성 손실이 있어 5th April, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: RVTY의 현재 순 이익률 (8.2%)은 지난해 (10.6%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RVTY의 수익은 지난 5년 동안 연평균 38.3% 감소했습니다.성장 가속화: RVTY은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: RVTY은 지난 1년 동안 수익이 감소(-18.9%)하여 Life Sciences 업계 평균(5.2%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: RVTY의 자본 수익률(3.3%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 22:30종가2026/06/17 00:00수익2026/04/05연간 수익2025/12/28데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Revvity, Inc.는 34명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Catherine Ramsey SchulteBairdCharles ButlerBarclaysLuke SergottBarclays31명의 분석가 더 보기
Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.37. Revenue: US$711.1m (up 7.0% from 1Q 2025). Net income: US$40.9m (down 1.9% from 1Q 2025). Profit margin: 5.8% (down from 6.3% in 1Q 2025). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.4%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.
공시 • Apr 11Revvity, Inc. to Report Q1, 2026 Results on May 05, 2026Revvity, Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026
Reported Earnings • Feb 02Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$2.06 (down from US$2.31 in FY 2024). Revenue: US$2.86b (up 3.7% from FY 2024). Net income: US$239.9m (down 15% from FY 2024). Profit margin: 8.4% (down from 10% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 8% per year.
Reported Earnings • Oct 28Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$0.41 (down from US$0.76 in 3Q 2024). Revenue: US$698.9m (up 2.2% from 3Q 2024). Net income: US$47.2m (down 49% from 3Q 2024). Profit margin: 6.8% (down from 14% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
공시 • Oct 06Revvity, Inc. to Report Q3, 2025 Results on Oct 27, 2025Revvity, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 27, 2025
분석 기사 • Aug 14Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings SuggestNYSE:RVTY 1 Year Share Price vs Fair Value Explore Revvity's Fair Values from the Community and select yours Even...
분석 기사 • 17hRevvity (RVTY) Stock Could Be 10.9% Undervalued Despite Profit And Growth PressureRevvity (RVTY) is back in focus after recent commentary highlighted weak organic revenue growth, declining adjusted operating profits, and ongoing annual earnings per share pressure. These factors are sharpening questions about the stock’s core business performance. See our latest analysis for Revvity. At a share price of $101.22, Revvity’s recent 30-day share price return of 7.72% and 90-day gain of 19.18% suggest momentum has picked up, even though the 5-year total shareholder return is...
내러티브 업데이트 • Jun 15RVTY: Elevated Multiple And China Exit Will Test 2026 ExecutionRevvity's analyst fair value estimate has shifted from $95.00 to $90.00 as analysts factor in more measured assumptions for revenue growth, profit margins, and a higher future P/E, while also weighing recent price target moves and mixed ratings across the Street. Analyst Commentary Recent Street research on Revvity shows a mix of views, with several firms adjusting ratings and price targets in different directions.
속보 • Jun 06Revvity Tops Q1 Estimates and Updates 2026 Outlook With China Unit Divestiture PlanRevvity reported Q1 2026 revenue of $711.1 million, up 7% year over year, with adjusted EPS of $1.06 coming in about 4% above Wall Street estimates. The company posted 3% total organic growth and an adjusted operating margin of 23.6% to 24%, supported by contributions from Life Sciences, Diagnostics and SaaS software. Revvity plans to divest its China Immunodiagnostics business, which represented about 6% of 2025 revenue, and expects the move to reduce adjusted EPS by about $0.15 in 2026 while lifting future organic growth by roughly 100 basis points and operating margins by about 30 basis points annually on a pro forma basis. The key story here is a business that is meeting or slightly topping expectations in the near term while reshaping its portfolio by exiting a segment that management views as a drag on growth and margins. Investors may want to weigh the near-term EPS headwind from the divestiture against the company’s updated 2026 guidance, which on a pro forma basis now points to $2.81 billion to $2.84 billion in revenue, adjusted EPS of $5.20 to $5.30 and organic growth of 3% to 4%. They may also want to monitor insider selling activity that has been reported over the past six months.
내러티브 업데이트 • Jun 01RVTY: Q1 Execution And Tools Demand Will Support Measured Future Earnings PowerRevvity's updated analyst price target has shifted to $113.64 from $119.56. This reflects a mix of recent target cuts and raises as analysts factor in revised growth and profitability assumptions, as well as a higher future P/E outlook.
Declared Dividend • May 11Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th July 2026 Payment date: 7th August 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 13%. Cash payout ratio: 6%.
분석 기사 • May 08Revvity, Inc. (NYSE:RVTY) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Shareholders of Revvity, Inc. ( NYSE:RVTY ) will be pleased this week, given that the stock price is up 14% to US$98.85...
Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.37. Revenue: US$711.1m (up 7.0% from 1Q 2025). Net income: US$40.9m (down 1.9% from 1Q 2025). Profit margin: 5.8% (down from 6.3% in 1Q 2025). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.4%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.
공시 • May 06Revvity, Inc. Updates Earnings Guidance for the Full Year 2026Revvity, Inc. Updated earnings guidance for the full year 2026. For the period, the company forecasts total revenue of $2.81-$2.84 billion.
내러티브 업데이트 • May 05RVTY: Cautious 2026 Tools Recovery Setup Will Face Execution DebateRevvity's updated analyst price target edges lower by $4 to reflect revised expectations following several price target cuts and a downgrade, partly offset by a recent upgrade from one research firm. Analyst Commentary Recent Street research on Revvity reflects a cautious tone, with several bearish analysts trimming price targets and reassessing expectations.
공시 • May 02Revvity, Inc. announces Quarterly dividend, payable on August 07, 2026Revvity, Inc. announced Quarterly dividend of USD 0.0700 per share payable on August 07, 2026, ex-date on July 17, 2026 and record date on July 17, 2026.
내러티브 업데이트 • Apr 21RVTY: 2026 Tools Recovery Setup Will Face Mixed Execution DebateThe analyst fair value estimate for Revvity has been reset from $105 to $95, as analysts weigh recent target cuts alongside mixed rating changes and revised assumptions for growth, margins, and future P/E multiples. Analyst Commentary Recent Street research on Revvity has sent mixed signals, with several price target adjustments and at least one downgrade alongside an upgrade.
공시 • Apr 17Revvity, Inc. Showcases Integrated Cancer Research Solutions At AACR Annual Meeting 2026Revvity, Inc. was showcasing its latest innovations in cancer research at the AACR Annual Meeting 2026, to be held in San Diego, April 17-22. The Company’s comprehensive suite of research use only (RUO) oncology solutions are designed to elevate preclinical and translational research workflows, helping scientists accelerate discoveries that drive the future of cancer science. The full scope of Revvity’s integrated oncology solutions and reagents that will be on display are designed to support the entire cancer research workflow from sample preparation and assay development, to advanced imaging, detection, and data analysis. By combining innovative technologies with AI-driven insights, Revvity helps researchers generate high-quality, reproducible data and uncover deeper biological insights faster. Attendees will experience several of Revvity’s latest innovations, including: Opera Phenix™ OptIQ high-content screening system for advanced 3D and live-cell imaging; Living Image™ Synergy AI software for multimodal in vivo imaging data analysis; EnVision Nexus™ One multimode plate reader for high-sensitivity detection and performance; AssayMate™ automated workstation for simplified, accessible sample preparation; Dharmacon™ ON-TARGETplus™ 2.0 siRNA for potent on-target mRNA knockdown with siRNA designed against the modern genome; Next-generation reagents and assay solutions, such as ATPlite™ and Spark PLUS UV395™, designed to enhance workflow consistency and data quality. Together, these solutions reflect Revvity’s strategy to deliver integrated technologies that connect workflows, reduce variability, and enable more confident decision-making in cancer research, including advanced cellular imaging, AI-enabled in vivo analysis, high-performance detection, automation, and genomics tools. By bringing together instrumentation, reagents, software, and services, Revvity supports researchers at every stage of the scientific journey, helping overcome complex research challenges, increase productivity, and translate discoveries into meaningful impact. For research use only. Not for use in diagnostic procedures. Not affiliated with or endorsed by AACR.
공시 • Apr 11Revvity, Inc. to Report Q1, 2026 Results on May 05, 2026Revvity, Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026
Upcoming Dividend • Apr 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 April 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.2%). Lower than average of industry peers (0.7%).
공시 • Apr 09Revvity Inc Announces Signals Biodesign Cloud-Native Molecular Cloning SolutionRevvity, Inc. announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration. The Signals BioDesign offering provides a complete solution for designing therapeutic constructs across core cloning workflows including Golden Gate, Gibson assembly, and restriction/ligation, plus primer design, Sanger sequencing analysis, and protein translation in one simple to use application. The solution enables high-throughput combinatorial cloning for up to 1,000 constructs while maintaining workflow simplicity, allowing pharma and biotech researchers to design faster, collaborate seamlessly, and eliminate costly data silos. As the only cloud-native molecular cloning tool with integration in the Signals One platform, the Signals BioDesign solution connects design with existing bioregistration and multi-modal experiment capture in a unified biologics research ecosystem. The cloud-native architecture enables real-time team collaboration, centralized bio-sequence libraries, duplicate checking, monomer management, and granular access controls that desktop tools cannot provide, while multi-tenant SaaS deployment eliminates the administrative overhead and compliance risks associated with desktop software licensing. The Signals BioDesign solution’s AI-ready data infrastructure also positions research teams for future machine learning applications in sequence optimization and predictive design. Revvity will introduce the Signals BioDesign offering at the Bio-IT World Conference & Expo, May 19-21, in Boston, Massachusetts.
내러티브 업데이트 • Apr 06RVTY: Recent Upgrade Cycle And Q4 Execution Will Drive Future UpsideRevvity's updated analyst price target edges up from $137.63 to $140.00 as analysts factor in a mix of recent target increases from several firms and a more cautious stance from at least one large bank. Analyst Commentary The latest Street research on Revvity reflects a split view, with several bullish analysts lifting price targets and one large bank taking a more cautious approach.
내러티브 업데이트 • Mar 23RVTY: 2026 Tools Recovery Setup Will Support Healthier End MarketsRevvity’s analyst price targets have shifted higher by a few dollars across several firms, with analysts pointing to healthier end markets, improving procedure and CapEx trends into 2026, early recovery signs in China, and expectations for the company’s tools exposure as key supports for the updated valuations. Analyst Commentary Recent Street research on Revvity has centered on how much recovery in tools demand and procedure volumes is already reflected in current valuations.
공시 • Mar 09Revvity, Inc., Annual General Meeting, Apr 28, 2026Revvity, Inc., Annual General Meeting, Apr 28, 2026.
내러티브 업데이트 • Mar 08RVTY: 2026 Tools Demand And China Recovery Will Support Higher Earnings PowerRevvity's analyst price target edges higher from $114.63 to $119.56 as analysts factor in updated assumptions around discount rates, modestly slower revenue growth and slightly lower profit margins, along with a higher future P/E multiple supported by a series of recent target raises from Baird, TD Cowen, Evercore ISI, Barclays and Jefferies. Analyst Commentary Bullish analysts have been lifting their price targets in a fairly tight range, which points to a shared view that Revvity's risk or return profile has shifted enough to justify higher valuation assumptions, even as they factor in tempered expectations for revenue growth and margins.
내러티브 업데이트 • Feb 22RVTY: Fair Value View Weighs 2026 Recovery Against Policy And China RisksAnalysts have nudged their targets on Revvity higher, with recent $3 to $6 price target increases clustered around a fresh $112 mark. They cite recovering end markets, healthier procedure and CapEx trends into 2026, and early signs of improvement in China as key supports for the updated view.
내러티브 업데이트 • Feb 08RVTY: Fair Value View Balances Margin Upside With Policy And China RisksAnalysts have lifted their implied fair value for Revvity by $5 to $105, citing updated assumptions around profit margins, a lower future P/E multiple, and recent price target increases from several firms as key drivers of the recalibration. Analyst Commentary Recent Street research on Revvity has centered on fine tuning price targets and reassessing how much investors are willing to pay for the company, with several firms adjusting their models around margin expectations and appropriate P/E levels.
Declared Dividend • Feb 08Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th April 2026 Payment date: 8th May 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 14%. Cash payout ratio: 6%.
공시 • Feb 05Revvity, Inc. Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations At SLAS2026Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are theOpera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include: Opera Phenix OptIQ high- content screening system: Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60% to 95%, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony software building block enables detection of organoids in brightfield image stacks. EnVision Nexus One multimode plates reader: The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the EnVision Nexus platform in a streamlined single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows. AssayMate workstation: The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3-1000 uL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling--including detection of missing plate lids--enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP software provides a user-friendly, drag-and-drop interface that requires minimal training.
Recent Insider Transactions Derivative • Feb 03Key Executive notifies of intention to sell stockTajinder Vohra intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of February. If the sale is conducted around the recent share price of US$105, it would amount to US$602k. Since March 2025, Tajinder's direct individual holding has decreased from 22.63k shares to 19.35k. Company insiders have collectively sold US$335k more than they bought, via options and on-market transactions in the last 12 months.
공시 • Feb 03Revvity, Inc. Provides Revenue Guidance Full Year Ending January 3, 2027Revvity, Inc. provided revenue guidance full year ending January 3, 2027. For the fiscal year 2026, the Company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%.
Reported Earnings • Feb 02Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$2.06 (down from US$2.31 in FY 2024). Revenue: US$2.86b (up 3.7% from FY 2024). Net income: US$239.9m (down 15% from FY 2024). Profit margin: 8.4% (down from 10% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 8% per year.
공시 • Jan 27Revvity, Inc. Declares Quarterly Dividend, Payable on May 8, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026.
내러티브 업데이트 • Jan 25RVTY: Q4 Margin Ramp And Sector Recovery Thesis Will Drive UpsideNarrative Update Analysts have lifted their price target on Revvity by about US$4 to reflect modestly higher fair value estimates and slightly stronger assumptions for revenue growth, Q4 execution and sector recovery potential into 2026. Analyst Commentary Bullish analysts are leaning constructive on Revvity, pointing to recent quarterly execution, updated guidance and sector trends as support for higher valuation ranges.
Major Estimate Revision • Jan 14Consensus EPS estimates increase by 18%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from US$2.06 to US$2.43. Revenue forecast steady at US$2.84b. Net income forecast to grow 45% next year vs 15% growth forecast for Life Sciences industry in the US. Consensus price target of US$115 unchanged from last update. Share price rose 8.3% to US$112 over the past week.
공시 • Jan 13+ 1 more updateRevvity, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2025Revvity, Inc. provided revenue guidance for the fourth quarter and full year of 2025. For the quarter, reported and organic revenue growth is expected to be approximately 6% and 4%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $772 million. For the full year 2025, reported and organic revenue growth is expected to be approximately 4% and 3%, respectively, as compared to the same period a year ago. This is expected to result in full year 2025 revenue of approximately $2,855 million.
내러티브 업데이트 • Jan 11RVTY: Q4 Margin Ramp And Buybacks Poised To Meet Cautious RecoveryThe analyst price target for Revvity has been nudged higher by about $0.25, reflecting Street analysts' generally constructive view on recovering end markets, Q4 guidance that many see as achievable, and improving sector sentiment, even as some firm specific and China related risks remain in focus. Analyst Commentary Street research on Revvity is mixed but tilts constructive, with several firms nudging price targets higher while one new initiation takes a more cautious stance.
Upcoming Dividend • Jan 09Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 16 January 2026. Payment date: 06 February 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.4%). Lower than average of industry peers (0.5%).
Buy Or Sell Opportunity • Jan 08Now 21% undervaluedOver the last 90 days, the stock has risen 15% to US$102. The fair value is estimated to be US$128, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.7% over the last 3 years. Earnings per share has declined by 23%. For the next 3 years, revenue is forecast to grow by 5.6% per annum. Earnings are also forecast to grow by 26% per annum over the same time period.
내러티브 업데이트 • Dec 27RVTY: Q4 Margin Ramp And Buybacks Will Drive Next PhaseAnalysts have nudged their average price target on Revvity modestly higher, reflecting confidence that Q4’s steeper ramp in sales and operating margins is achievable and supported by in-line Q3 organic growth, an earnings beat, and slightly improved forward earnings guidance, despite lingering company specific and macro headwinds. Analyst Commentary Bullish analysts highlight that Q3, while not spectacular, provides a solid springboard for a steeper ramp in Q4 sales and operating margins, which they view as achievable based on in line organic growth and an earnings beat.
분석 기사 • Dec 18Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
공시 • Dec 17Revvity, Inc. Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials DiscoveryRevvity, Inc. announced the introduction of its upcoming Signals Xynthetica™? Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in-silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence. Across life sciences and materials research, the application of artificial intelligence and machine learning is rapidly shifting discovery from trial-and-error experimentation toward predictive, data driven design. While powerful algorithms and models continue to emerge, their real-world impact is limited without tight integration with high-quality experimental data and the workflows scientists already use. The Signals Xynthedica offering is intended to address this gap by embedding models directly into the scientific context, connecting AI predictions with real wet-lab outcomes to drive continuous learning and improvement. The Signals Xyntetica platform will support a wide range of in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. Delivered as an AI MaaS offering, it enables organizations to access, govern, and apply predictive models without building or maintaining a complex AI infrastructure. Models can be used consistently across projects, refreshed as new data emerges, and evaluated transparently alongside experimental results. The Signals Xynthenica offering is expected to become a cornerstone of Revvity's broader vision for AI-augmented discovery, enabling customers to harness predictive power at scale while maintaining strong governance, data stewardship, and scientific rigor. Pre-registration for customers is underway with early access programs available in firstH 2026.
내러티브 업데이트 • Dec 13RVTY Q4 Margin Ramp And Buybacks Will Drive Stronger Future UpsideAnalysts have modestly raised their blended price target on Revvity to approximately $105 per share, up from around $100. This change reflects increased confidence that the company can deliver a steeper but achievable ramp in Q4 sales and margins while continuing to improve profitability, despite a slightly higher discount rate and lingering near term growth risks.
Buy Or Sell Opportunity • Dec 01Now 20% undervaluedOver the last 90 days, the stock has risen 17% to US$102. The fair value is estimated to be US$129, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.7% over the last 3 years. Earnings per share has declined by 23%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 29% per annum over the same time period.
내러티브 업데이트 • Nov 29RVTY: Buyback Program and Guidance Outlook Will Shape Next PhaseAnalysts have increased their price target for Revvity to $105 from previous levels. They cite achievable Q4 guidance and an improved profit outlook, despite mixed quarterly results.
내러티브 업데이트 • Nov 15RVTY: Recent Buyback Activity and Expanded Partnership Will Drive Near-Term MomentumRevvity's analyst price target has increased from $99 to $105 per share, as analysts cite improving guidance for the upcoming quarter and stronger than expected recent performance, while noting that some risks remain. Analyst Commentary Analyst sentiment towards Revvity has shifted positively in recent weeks, reflecting improved financial guidance and resilient performance.
공시 • Nov 10Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc.Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc. on November 10, 2025. The transaction is expected to close late in Q4 2025.
Declared Dividend • Nov 09Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 16th January 2026 Payment date: 6th February 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 14%. Cash payout ratio: 6%.
내러티브 업데이트 • Oct 31RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery AheadAnalysts have slightly raised their fair value estimate for Revvity by $1 to $113.67. They cite more achievable Q4 guidance and improved margin prospects following the company's recent earnings updates.
Reported Earnings • Oct 28Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$0.41 (down from US$0.76 in 3Q 2024). Revenue: US$698.9m (up 2.2% from 3Q 2024). Net income: US$47.2m (down 49% from 3Q 2024). Profit margin: 6.8% (down from 14% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
공시 • Oct 27Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares.Revvity, Inc. (NYSE:RVTY) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its own shares. The program is valid for 2 years.
Seeking Alpha • Oct 27Revvity: Software Momentum And Screening Offset China WeaknessSummary Revvity, Inc. operates across two main segments in Life Sciences tools and Diagnostics. Its cloud informatics Signals continue experiencing double-digit growth, while diagnostics in China suffer from macro headwinds. RVTY’s latest Q3 2025 revenue figures were up 2% overall. For the most part, US and ex-China growth offsets China’s decline. In my view, its valuation is about fair, but there’s room for upside as the stock should catch up to the rest of the market given its EPS recent beat. RVTY’s cash flow remains solid, and the $1 billion buyback program should further help the stock price over the next few months. Read the full article on Seeking Alpha
공시 • Oct 27Revvity, Inc. Revises Earnings Guidance for the Full Year Ending December 28, 2025Revvity, Inc. revised earnings guidance for the full year ending December 28, 2025. For the year, the company expects revenue to be between $2.83 billion to $2.88 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 2% to 4%.
공시 • Oct 25Revvity, Inc. Appoints Anita Gonzales as Vice President and Chief Accounting Officer, Effective October 23, 2025On October 23, 2025, the Board of Directors of Revvity, Inc. appointed Anita Gonzales, the Company’s Vice President and Controller, to serve as its Vice President and Chief Accounting Officer, effective October 23, 2025. Mrs. Gonzales, 49, has served as the Company’s Vice President and Controller since May 2023, having joined the Company as Senior Director of Integration and Controllership Initiatives in March 2021. Prior to joining the Company, Mrs. Gonzales was at General Electric Company (“GE”) for ten years. During her tenure at GE, Mrs. Gonzales was Director of Audit and Advisory Practices Corporate division from 2016 to 2021, with responsibility for technical accounting and audit standards of the Corporate Audit Staff. Before that, Mrs. Gonzales held executive roles at GE Aviation including Global Controller-Commercial Engines. Earlier in her career, she held roles of increasing responsibility, up to Senior Manager, at PricewaterhouseCoopers. Mrs. Gonzales holds Master of Public Accounting and Bachelor of Business Administration degrees from the University of Texas at Austin and is a Certified Public Accountant.
공시 • Oct 24Revvity Board Declares Quarterly Dividend, Payable on February 6, 2026The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.
내러티브 업데이트 • Oct 17Digital Transformation And Advanced Diagnostics Will Create Enduring ValueThe consensus analyst price target for Revvity has decreased from $115.19 to $112.67. This change reflects lowered profit margin forecasts, slower revenue growth expectations, and continued market headwinds highlighted in recent research reports.
Upcoming Dividend • Oct 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 October 2025. Payment date: 07 November 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.5%). Lower than average of industry peers (0.5%).
공시 • Oct 06Revvity, Inc. to Report Q3, 2025 Results on Oct 27, 2025Revvity, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 27, 2025
내러티브 업데이트 • Oct 03Digital Transformation And Advanced Diagnostics Will Create Enduring ValueAnalysts have slightly reduced their price target for Revvity by $1.63 to $115.19. They cite cautious optimism, as stable core markets are offset by ongoing sector uncertainties and revised forecasts for a slower recovery.
공시 • Sep 30Revvity, Inc. Unveils New AI Software Offering to Transform Preclinical Imaging AnalysisRevvity, Inc. announced the launch of its Living Image Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities--reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. The Living Image Synergy AI software centralizes analysis with a goal of eliminating the need for separate tools and enabling seamless correlation of datasets. Revvity developed this unified approach to help researchers uncover biological insights that might otherwise remain hidden when using isolated systems. To further streamline workflows, the software features intuitive co-registration tools and automated processes that reduce manual tasks and analysis time. Advanced AI algorithms automate image segmentation and region-of-interest (ROI) quantification--traditionally labor-intensive and variable steps in imaging analysis. This helps support high-throughput analysis and allows researchers to more efficiently monitor disease progression and assess therapeutic efficacy with greater accuracy and statistical confidence.
공시 • Sep 22Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD)Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD)
분석 기사 • Aug 14Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings SuggestNYSE:RVTY 1 Year Share Price vs Fair Value Explore Revvity's Fair Values from the Community and select yours Even...
Declared Dividend • Aug 10Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th October 2025 Payment date: 7th November 2025 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 7%.
공시 • Aug 07Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted TherapeuticsRevvity, Inc. announced the launch of pHSense™? reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to- background--even at low endogenous receptor expression levels. Fully compatible with Revvity's multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows. By enabling more efficient screening and characterization of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation. With a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design focused on addressing major limitations of current offerings such as low throughput and suboptimal signal-to-noise ratios.
Reported Earnings • Jul 29Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: EPS: US$0.47 (down from US$0.59 in 2Q 2024). Revenue: US$720.3m (up 4.1% from 2Q 2024). Net income: US$55.2m (down 24% from 2Q 2024). Profit margin: 7.7% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
공시 • Jul 29Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.84 billion to $2.88 billion to reflect recent changes in foreign currency exchange rates and assumes 2% to 4% organic growth.
공시 • Jul 25Revvity, Inc. Declares Quarterly Dividend, Payable on November 7, 2025The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025.
분석 기사 • Jul 22Investors Interested In Revvity, Inc.'s (NYSE:RVTY) EarningsWhen close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...
Upcoming Dividend • Jul 11Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 18 July 2025. Payment date: 08 August 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.5%). Lower than average of industry peers (0.6%).
공시 • Jul 07Revvity, Inc. to Report Q2, 2025 Results on Jul 28, 2025Revvity, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 28, 2025
분석 기사 • Jul 04Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101?Revvity, Inc. ( NYSE:RVTY ) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE...
공시 • Jun 02Revvity, Inc. Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing WorkflowsRevvity, Inc. announced the launch of three Mimix reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requirements, which helps laboratories integrate them into existing workflows to support monitoring test performance, assay variation, and to help identify increases in random or systemic errors. Offering the Mimix reference standards for IV D indicates the products have been developed and manufactured in accordance with applicable quality system requirements allowing for improved reliability and precision of these reference standards. The three Mimix reference standards cover key cancer testing applications, which include: Mimix OncoSpan FFPE Reference Standard IVD (HD832-IVD); Mimix OncoSpan gDNA Reference Standard IVD (HD 827-IVD); Mimix Myeloid Cancer Panel, gDNA Reference Standard IVD.
공시 • May 20Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty TestingRevvity, Inc. announced the launch of its new IDS i20™? analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer's disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low-throughput analyzers, the IDS i20 platform offers labs a new means of more flexible, fully automated ChLIA processing. With the ability to process up to 140 tests per hour (assay dependent), the IDS i20 instrument is the latest addition to the well-established IDS i-device series, built on more than 50 years of experience in medical device design and innovation. The IDS i20 platform features new software offering a high degree of adaptability and scalability, along with a superior graphical user interface that meets the latest standards of ergonomics, usability and cybersecurity. Continuous loading of samples and reagents as well as the integrated cooling of ready-to-use reagent cartridges allow for non-stop operation of the system - maximizing efficiency and minimizing hands-on time.
Declared Dividend • May 11Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 18th July 2025 Payment date: 8th August 2025 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 6%.
Reported Earnings • Apr 28First quarter 2025 earnings: EPS exceeds analyst expectationsFirst quarter 2025 results: EPS: US$0.35 (up from US$0.23 in 1Q 2024). Revenue: US$664.8m (up 2.3% from 1Q 2024). Net income: US$41.7m (up 45% from 1Q 2024). Profit margin: 6.3% (up from 4.4% in 1Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
공시 • Apr 28Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.83-$2.87 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 3-5% for the full year 2025.
공시 • Apr 25Revvity, Inc. Declares Regular Quarterly Dividend, Payable on August 8, 2025The Board of Directors of Revvity declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025.
공시 • Apr 23Revvity, Inc. Fuels the Future of Cancer Science with New Research SolutionsRevvity, Inc. is set to unveil the VivoJect™? Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Meeting 2025 in Chicago, April 25-30. Paired with the Vega™? automated preclinical ultrasound system, the VivoJect system allows for real-time imaging and precise, nimble operation for researchers at a higher throughput compared to traditional techniques. It streamlines in vivo imaging workflows for applications such as tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies. Revvity will also showcase a broad portfolio of solutions driving advancements in cancer research at its booth (#1200), including the PhenoVue™? DNA Damage Response Staining Kit, Harmony™? 5.3 and Phenologic.AI™? high-content image analysis software and over 120 cell line-derived oncology reference standards from itsimix™? portfolio. BioLegend's reagent innovations will also be on display, including the TotalSeq™? PhenoCyte, TotalSeq-A and -C Universal Cocktails, v2.0, LEGEND MAX™? High Sensitivity Mouse TNF-a and ELISA MAX™? Deluxe Set Human ICAM-1 kits. Key Exhibits at AACR Annual Meeting 2025 Revvity's booth will also feature: Cell analysis in 3D, and AI: Solutions include cell counters and image cytometers, cellular imaging reagents, microplates and analysis software, as well as high-content imaging instruments. Immunoassays: An extensive range of immunoassay technologies including multimode microplate readers and microplates, as well as assay kits and reagents. In vivo imaging: Instruments, reagents, software and related accessories to help accelerate drug development by tracking disease progression, evaluate efficacy, and assess toxicity. Genomic solutions: A wide range of solutions including the Pin-point™? base editing platform, OMNI™? sample homogenizers, liquid handling workstations and more. More than 10 scientific posters authored or co-authored by Revvity employees will be on display. Among them is a poster produced in collaboration with a research team from Charles River Laboratories, which utilized Revvity's Vega automated preclinical ultrasound system in a longitudinal study of the progression of graft versus host disease. For further information on Revvity's cancer research innovations and poster presentations at the AACR Annual meeting 2025, visit booth #1200 or this link. All Revvity offerings mentioned herein are for research use only, and not for use in diagnostic procedures.
Upcoming Dividend • Apr 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 April 2025. Payment date: 09 May 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.9%). Lower than average of industry peers (0.7%).
Buy Or Sell Opportunity • Apr 08Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to US$91.79. The fair value is estimated to be US$118, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has declined by 54%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
공시 • Apr 03Revvity, Inc. to Report Q1, 2025 Results on Apr 28, 2025Revvity, Inc. announced that they will report Q1, 2025 results Pre-Market on Apr 28, 2025
공시 • Apr 02Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis TestRevvity, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world. Key Features of the Automated Latent Tuberculosis Test: The Auto-Pure 2400 system seamlessly integrates liquid handling and magnetic cell isolation technology. The Auto-Pure 2400 system streamlines lab workflows, testing up to 24 samples per run, completing Day 1 of the T-SPOT.TB testing in under 3.5 hours with only a single mid-run user interaction. The WHO identifies T-SPOT.TB as the only ELISPOT-based IGRA. This methodology, with its added cell number normalization step, ensures reproducible results by minimizing the impact of pre-analytical variables seen in other IGRAs. The T-SPOT.TB test delivers key advantages, including fewer indeterminate results, reduced need for repeat testing, and consistent performance in immunocompromised patients.
공시 • Feb 27Revvity, Inc., Annual General Meeting, Apr 22, 2025Revvity, Inc., Annual General Meeting, Apr 22, 2025.
Seeking Alpha • Feb 24Revvity: Acquisitions In High-Growth Sectors, Excellent Debt Levels Create Notable Growth PotentialSummary Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position, reaching a 38.13% liabilities-to-assets ratio, the lowest value in eight years. In addition, it has improved its current ratio. Despite the fact that Revvity will face a weak demand in 2025, the two segments of Revvity expect a high growth rate in the long-term. Read the full article on Seeking Alpha
Declared Dividend • Feb 09Dividend of US$0.07 announcedShareholders will receive a dividend of US$0.07. Ex-date: 17th April 2025 Payment date: 9th May 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.4%. Payout Ratios Payout ratio: 12%. Cash payout ratio: 6%.
Reported Earnings • Feb 01Third quarter 2024 earnings released: EPS: US$0.76 (vs US$0.26 in 3Q 2023)Third quarter 2024 results: EPS: US$0.76 (up from US$0.26 in 3Q 2023). Revenue: US$684.0m (up 2.0% from 3Q 2023). Net income: US$93.4m (up 188% from 3Q 2023). Profit margin: 14% (up from 4.8% in 3Q 2023). Revenue is forecast to grow 5.1% p.a. on average during the next 4 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions Derivative • Jan 31Senior VP of Administration notifies of intention to sell stockJoel Goldberg intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of January. If the sale is conducted around the recent share price of US$127, it would amount to US$1.9m. Since March 2024, Joel's direct individual holding has decreased from 104.61k shares to 97.11k. Company insiders have collectively sold US$818k more than they bought, via options and on-market transactions in the last 12 months.
공시 • Jan 31Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025Revvity, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects total revenue of $2.80 billion to $2.85 billion.
공시 • Jan 24+ 1 more updateRevvity, Inc. to Unveils New Phenologic.AI Software At SLAS2025 in San Diego, San DiegoRevvity, Inc. is set to unveil its groundbreaking new Phenologic.AI software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity’s Harmony™ and Signals Image Artist software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis. This significant advancement expands the possibilities for understanding cellular behaviors and disease mechanisms. The Phenologic.AI offering provides scalable, efficient, and objective analysis and can be integrated with Revvity Signals Research Suite™ to provide more in-depth data analytics. Complementing this launch, Revvity will also introduce other notable products, including the latest Harmony 5.3 software, which simplifies data management for high-content imaging and analysis, providing faster and more intuitive data handling. Key Exhibits at SLAS2025: Revvity’s featured solutions include: Assay Development and Automation: Custom automation solutions to boost throughput and reliability, including the explorer™ G3 integrated workstation. Automated Liquid Handling: The Fontus liquid handler offers intuitive software, optimized protocols, and reformatting capabilities for streamlined productivity. Cell Imaging and AI: Advanced tools like the Opera Phenix Plus HCS system, alongside the Phenologic.AI offering. Reagents Portfolio: Including PhenoVue imaging reagents, BioLegend antibodies, and Dharmacon CRISPR screening libraries. For detailed information on the showcased innovations, scientific talks, and posters, visit booth #1318 or Revvity’s SLAS2025 events page.
공시 • Jan 16Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024Revvity, Inc. updated revenue guidance for the fourth quarter of 2024. For the year, the company's Reported and organic revenue growth for the fourth quarter is expected to be approximately 5% and 6%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $730 million.
공시 • Jan 13Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025Revvity, Inc. announced that they will report fiscal year 2024 results Pre-Market on Jan 31, 2025
Recent Insider Transactions Derivative • Jan 12Key Executive notifies of intention to sell stockTajinder Vohra intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of January. If the sale is conducted around the recent share price of US$117, it would amount to US$642k. Since March 2024, Tajinder's direct individual holding has decreased from 26.11k shares to 19.65k. Company insiders have collectively sold US$818k more than they bought, via options and on-market transactions in the last 12 months.
공시 • Jan 10Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone TestRevvity, Inc. announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders. Key features of the new test include: The only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma. Rapid results on EUROIMMUN’s ChLIA platforms with the first result available in just 48 minutes and an estimated throughput of nearly 60 tests per hour. Incorporation of monoclonal antibodies to ensure specificity and consistent performance across test batches. The assay is processed on the Company’s random-access iSYS or i10 instruments to deliver quick turnaround times and high-throughput testing with minimal technician training and expertise, while maintaining superior accuracy and reliability. The assay provides direct measurement of free testosterone levels in a single test, enhancing diagnostic capabilities for conditions such as hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgenital syndromes.
Upcoming Dividend • Jan 10Upcoming dividend of US$0.07 per shareEligible shareholders must have bought the stock before 17 January 2025. Payment date: 07 February 2025. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of American dividend payers (4.6%). Lower than average of industry peers (0.5%).
Seeking Alpha • Dec 16Safe Biopharma: Revvity's Recurring Revenues And DiagnosticsSummary Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company’s recurring revenue base (80%) from consumables, services, and software ensures predictable income and financial stability. The company has a global footprint and an estimated TAM exceeding $60 billion, showcasing its significant market opportunity. Yet, RVTY's valuation is relatively high compared to peers, with a forward PE of 22.7 and an earnings yield of 4.4%, reflecting its premium status. Despite sluggish revenue growth, RVTY's diversified revenue sources and strong cash flow make it a safe long-term buy in the biopharma sector. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • Dec 03CEO, President & Director notifies of intention to sell stockPrahlad Singh intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of December. If the sale is conducted around the recent share price of US$116, it would amount to US$2.1m. For the year to December 2017, Prahlad's total compensation was 12% salary and 88% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Prahlad has owned 127.36k shares directly. Company insiders have collectively bought US$18k more than they sold, via options and on-market transactions, in the last 12 months.
공시 • Nov 20Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single CellsScale Biosciences (Scale BioTM) and Revvity's BioLegend business announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Biosciences' Quantum Barcoding technology platform and BioLegend's TotalSeqTM antibody conjugates. While technologies like mass cytometry and high-parameter flow cytometry enable protein analysis at the single cell level, these approaches require complex panel optimization and sophisticated instrumentation that limit their accessibility and scalability across multiple samples. The new offering builds upon BioLegend's well validated TotalSeq-ATM antibody panels and Scale Bio's Quantum Barcoding technology workflow. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation. The TotalSeq Phenocyte solution is now shipping.
